MedPath
Found 1 clinical trials|View Analysis
Sort by:

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2
Recruiting
Conditions
Relapsed/refractory Diffuse Large B-cell Lymphoma
Interventions
First Posted Date
2020-06-22
Last Posted Date
2024-07-24
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
501
Registration Number
NCT04442022
Locations
🇺🇸

Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona, United States

🇺🇸

Arizona Oncology Associates, Tucson, Arizona, United States

🇺🇸

The Oncology Institute (TOI) Clinical Research, Cerritos, California, United States

and more 54 locations
© Copyright 2025. All Rights Reserved by MedPath